| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
,¶
Departments of
*
Dermatology,
Laboratory Medicine, and
Pathology, and Sections of
Immunobiology and
¶
Medical Oncology and Hematology, Yale University School of Medicine, New Haven, CT 06520
Chronic graft-vs-host disease (cGVHD) is an increasingly frequent complication of allogeneic stem cell transplantation. Phenotypically, cGVHD differs from patient to patient; in particular, a subset of patients develops extensive cutaneous fibrosis. Similarly, graft-vs-host disease (GVHD) is distinct in inbred murine donor:recipient pairings, indicating a genetic component to disease phenotype. The B10.D2 
BALB/c (H-2d) strain pairing uniquely recapitulates key pathologic features of fibrotic human cutaneous cGVHD. To distinguish whether this genetic component is due to differences in genes that modulate immune responses or to the specific Ags targeted, we asked whether skin-dominant cGVHD also develops in the B10 BALB.B (H-2b) and B10.BR BALB.K (H-2k) MHC-congenic pairings. Because each MHC haplotype presents different peptides and selects different T cell repertoires, GVHD in each donor:recipient pair undoubtedly targets different Ags. We found that, in contrast to BALB/c recipients, BALB.B mice never manifested skin disease while BALB.K mice developed a modified form of skin disease. Instead, BALB.B and BALB.K recipients developed systemic GVHD which was absent in BALB/c mice. Moreover, in (B10 x B10.D2)F1 (BALB.B x BALB/c)F1 H-2b/d transplants, recipients developed both cutaneous and systemic disease. Thus, the selection of immunodominant Ags determines the target and character of GVHD, providing insight into the genetic basis for different forms of GVHD.
This article has been cited by other articles:
|
|
 |
|
  A. Ghosh, W. Koestner, M. Hapke, V. Schlaphoff, F. Langer, R. Baumann, C. Koenecke, M. Cornberg, K. Welte, B. R. Blazar, et al. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras Blood, April 30, 2009; 113(18): 4440 - 4448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Pillai, T. I. George, S. Dutt, and S. Strober Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease Blood, April 30, 2009; 113(18): 4458 - 4467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Li, Y. Chen, W. He, T. Yi, D. Zhao, C. Zhang, C.-L. Lin, I. Todorov, F. Kandeel, S. Forman, et al. Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI Blood, January 22, 2009; 113(4): 953 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kim, K. Park, H. J. Kim, J. Kim, H.-A Kim, D. Jung, H. J. Kim, H.-J. Choi, S.-Y. Choi, K. W. Seo, et al. Breaking of CD8+ T Cell Tolerance through In Vivo Ligation of CD40 Results in Inhibition of Chronic Graft-versus-Host Disease and Complete Donor Cell Engraftment J. Immunol., November 15, 2008; 181(10): 7380 - 7389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhao, C. Zhang, T. Yi, C.-L. Lin, I. Todorov, F. Kandeel, S. Forman, and D. Zeng In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease Blood, September 1, 2008; 112(5): 2129 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yi, D. Zhao, C.-L. Lin, C. Zhang, Y. Chen, I. Todorov, T. LeBon, F. Kandeel, S. Forman, and D. Zeng Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease Blood, September 1, 2008; 112(5): 2101 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Anderson, P. A. Taylor, J. M. McNiff, D. Jain, A. J. Demetris, A. Panoskaltsis-Mortari, A. Ager, B. R. Blazar, W. D. Shlomchik, and M. J. Shlomchik Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells Blood, May 15, 2008; 111(10): 5242 - 5251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Matte-Martone, J. Liu, D. Jain, J. McNiff, and W. D. Shlomchik CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL Blood, April 1, 2008; 111(7): 3884 - 3892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dutt, D. Tseng, J. Ermann, T. I. George, Y. P. Liu, C. R. Davis, C. G. Fathman, and S. Strober Naive and Memory T Cells Induce Different Types of Graft-versus-Host Disease J. Immunol., November 15, 2007; 179(10): 6547 - 6554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kim, H. J. Kim, K. Park, J. Kim, H.-J. Choi, H. Yagita, S. H. Nam, H. R. Cho, and B. Kwon Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease Blood, July 15, 2007; 110(2): 776 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Pillai, T. I. George, S. Dutt, P. Teo, and S. Strober Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation J. Immunol., May 15, 2007; 178(10): 6242 - 6251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. de Witte, M. Toebes, J.-Y. Song, M. C. Wolkers, and T. N. M. Schumacher Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease Blood, May 1, 2007; 109(9): 3830 - 3838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Blood, February 15, 2007; 109(4): 1756 - 1764. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
